The IZAR-1 readout is the second clean Phase 3 win after VELA in HS, substantially expanding sonelokimab's addressable market. Next catalysts: BLA submission for HS (end Sep 2026) and IZAR-2 enrollment completion (Q3 2026). The $83.6M share count reflects equity raises in Q2; monitor for post-data dilution. The positive safety/efficacy profile supports bullish positioning into the BLA milestone.
Price Chart
Executive Summary
MoonLake announced positive topline Phase 3 IZAR-1 results for sonelokimab in psoriatic arthritis, meeting all clinical endpoints at Week 16 with a 42.1% ACR50 response, alongside Q2 2026 financial results showing a net loss of $61.8M and $537M in cash. The positive trial data de-risks the PsA indication and expands the pipeline beyond lead HS, while cash runway extends to mid-2028.
Key Financial Metrics
Key Facts
- Phase 3 IZAR-1 trial met all clinical endpoints at Week 16 for 60 mg sonelokimab in PsA.
- 42.1% of bio-naïve patients achieved ACR50 at Week 16.
- Key secondary endpoints: ACR20 66.5%, MDA 41.2%, PASI90 61%.
- Blinded safety profile consistent with prior studies; no new safety signals.
- Q2 2026 cash and equivalents $537M; cash runway to mid-2028.
- BLA submission for sonelokimab in HS expected end of September 2026.
- Net loss for Q2 2026: $61.8M ($0.84/share) vs $69.7M ($0.98/share) in Q1 2026.
- Shares outstanding increased from 72.1M to 83.6M quarter-over-quarter.
Financial Impact
Positive Phase 3 data in a new multi-billion dollar indication (PsA) significantly increases the probability-weighted pipeline value for sonelokimab; cash position of $537M provides runway to mid-2028.
Risk Factors
- IZAR-1 comparative vs placebo data remains blinded; full week 52 readout not until H1 2027.
- Significant share dilution in Q2 2026 (72.1M to 83.6M shares outstanding).
- No revenue until commercial launch, expected H2 2027 at earliest.
- BLA submission and FDA review for HS carry regulatory risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-086939 |
| Document: ea0301191-8k_moonlake.htm | 0001213900-26-086939 |
| Document: 0001213900-26-086939-index-headers.html | 0001213900-26-086939 |
| Document: 0001213900-26-086939-index.html | 0001213900-26-086939 |
| Document: 0001213900-26-086939.txt | 0001213900-26-086939 |
| 8-K Data (Synthetic) | 0001213900-26-086939 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 10w ago | Institutional Cluster | $17.23 | awaiting T+60 | — | $11.85 (−31.22%) |
Aug 10, 2026 11w ago | 8-K | $17.33 | awaiting T+60 | — | $11.85 (−31.62%) |
Aug 10, 2026 11w ago | Press Release | $17.33 | awaiting T+60 | — | $11.85 (−31.62%) |
Jul 20, 2026 14w ago | Insider Cluster | $19.05 $10.41 | ▲ +45.35% | ▲ +50.19% | $11.85 (+37.80%) |
Jun 25, 2026 17w ago | 8-K | $19.99 $12.39 | ▲ +38.02% | ▲ +41.87% | $11.85 (+40.72%) |
Jun 23, 2026 17w ago | Press Release | $20.00 $12.20 | ▲ +39.00% | ▲ +42.29% | $11.85 (+40.75%) |
Jun 22, 2026 18w ago | 8-K | $22.16 $12.20 | ▼ −44.95% | ▼ −46.69% | $11.85 (−46.53%) |
Jun 21, 2026 18w ago | Press Release | $22.16 $12.20 | ▼ −44.95% | ▼ −46.69% | $11.85 (−46.53%) |
Jun 11, 2026 19w ago | Institutional Cluster | $17.75 $15.01 | ▲ +15.44% | ▲ +19.83% | $11.85 (+33.24%) |
Jun 1, 2026 21w ago | 8-K | $18.82 $15.56 | ▼ −17.32% | ▼ −18.55% | $11.85 (−37.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers